Medical Access in Senegal

Currently classified as a strictly controlled substance under Senegalese narcotics and drug‑control legislation, with no authorized medical use outside of approved clinical research. [1]MemoireOnline – Senegal drug law review [2]UNODC database – example regional drug‑control law

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. [1]MemoireOnline – Senegal drug law review [2]UNODC database – example regional drug‑control law

No substantiated public record of a national marketing authorization or routine clinical reimbursement pathway for esketamine (Spravato) in Senegal; as with other novel psychoactive therapeutics, access would require an authorization of a marketing application by the national medicines regulator or participation in a sanctioned clinical trial. The national regulator and oversight for medicines is administered via the Ministry of Health / Direction de la Pharmacie et du Médicament, which handles marketing authorizations and pharmacovigilance in Senegal. [1]Ministère de la Santé – Direction de la Pharmacie et du Médicament For novel agents lacking a formal national registration, the only lawful pathways are an approved clinical trial or an exceptional import/compassionate use authorization from the Ministry/Direction of Pharmacy; otherwise the compound would be treated under strict controlled‑substance provisions. [2]MemoireOnline – Senegal drug law review

Ketamine is an established medical anesthetic in Senegal and is listed on national essential‑medicines/health facility medicine lists for use as an injectable anesthetic, indicating routine medical availability and use in public and private hospitals. The Senegal national essential medicines lists and procurement catalogues include injectable ketamine preparations (e.g., Ketalar 50 mg) as a standard anesthetic. [1]Liste Médicaments Essentiels Sénégal (national medicines list) [2]Liste des Médicaments Essentiels – archive/document copies Regulatory oversight for ketamine distribution and marketing authorizations is exercised by the Ministry of Health’s Direction de la Pharmacie et du Médicament (the competent national authority for marketing authorizations, pharmacovigilance and hospital medicines). [3]Ministère de la Santé – Direction de la Pharmacie et du Médicament Practical notes on access and reimbursement: ketamine is procured and stocked by public hospitals (included on EML lists) and therefore dispensed within hospital settings; explicit nationwide outpatient/ambulatory reimbursement rules for off‑label psychiatric ketamine infusions are not publicly documented and would typically depend on hospital/clinic billing policies and any social insurance or mutual coverage arrangements in place for inpatient/surgical anesthetic care. The country has active law‑enforcement efforts targeting diversion of ketamine (large seizures reported), underscoring that non‑medical possession or diversion is criminalized. [4]Senego – reports of large drug seizures incl. ketamine

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Preparations containing DMT (including ayahuasca) have no routine medical reimbursement or authorized clinical pathway in Senegal outside trial settings. [1]MemoireOnline – Senegal drug law review [2]UNODC database – example regional drug‑control law

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. [1]MemoireOnline – Senegal drug law review [2]UNODC database – example regional drug‑control law

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. There are no public records of a national regulatory program authorizing ibogaine for addiction treatment or other medical indications in Senegal. [1]MemoireOnline – Senegal drug law review [2]UNODC database – example regional drug‑control law

Preparations containing DMT (e.g., ayahuasca) are effectively treated under the same controlled‑substance framework and have no authorized medical/reimbursed status outside approved clinical research or explicit, narrow legal exemptions; routine therapeutic or religious exemptions recognized in other jurisdictions are not documented for Senegal. [1]MemoireOnline – Senegal drug law review [2]UNODC database – example regional drug‑control law

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research; possession, cultivation or trafficking of mescaline or mescaline‑containing preparations would fall under general narcotics prohibitions unless specifically permitted by law (no such permit for religious use has been documented in Senegal). [1]MemoireOnline – Senegal drug law review [2]UNODC database – example regional drug‑control law

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Novel synthetic phenethylamines such as the 2C family are treated as illicit/controlled and subject to criminal penalties for manufacture, possession or distribution. [1]MemoireOnline – Senegal drug law review [2]UNODC database – example regional drug‑control law